Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
Phase II Trial of Stereotactic Body Radiation Therapy Compared With Conventional Fractionated Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
研究概览
地位
条件
详细说明
Non small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Approximately half of all patients with NSCLC present with metastatic disease at the time of diagnosis, and the predominant pattern of failure in patients with localized NSCLC is distant metastatic spread. The standard treatment in metastatic disease is cytotoxic chemotherapy with a mean overall survival between 8-11 months.
Various studies suggest that patients who clinically present with a limited number of metastases, a term defined as oligometastatic disease, could have a better prognosis of survival with a radical treatment, than for their counterparts with a greater number of metastasis. Much of the current clinical outcomes in oligometastatic disease is based on a series of the retrospective studies.
This is a randomised prospective phase II study based on patients with stage IV oligometastatic NSCLC according to UICC stage system(version 7,2009) or oligometastatic disease after radical operation for stage I-III NSCLC. The purpose of this study is to add more information to the current medical literature about the efficacy and safety of Stereotactic Body Radiation Therapy (SBRT) compared with conventional fractionated radiotherapy for oligometastatic non-small cell lung cancer (equal to or less than 5 sites and equal to or less than 5cm in maximum diameter).
The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into two groups. The control group will undergo the conventional fractionated radiotherapy to all metastatic sites and the primary tumor. The experimental group will receive SBRT to primary lesions or metastatic lesions.
The investigators will compare progress free survival(PFS) ,overall survival, incidence of treatment-related adverse events of the two groups.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Shanghai
-
Shanghai、Shanghai、中国
- Shanghai Chest Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically proven non-small-cell lung cancer.
- Stage IV oligometastatic NSCLC according to UICC stage system(version 7,2009) or oligometastatic disease after radical operation for stage I-III NSCLC.
- The patients receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response).
- Staging with chest CT scan, abdominal ultrasonography , MRI brain, Bone scan and/or FDG PET-CT whole body scan.
- Number of metastatic lesions equal to or less than 5.
- Maximum diameter of metastatic tumors equal to or less than 5cm.
- ECOG performance status 0-2 at time of registration.
- EGFR testing is mandatory.
- No brain metastasis in MRI.
- No liver metastasis in abdominal CT or MRI.
- No malignant pleural effusion or pericardial effusion or peritoneal effusion.
- Acceptable lung function for radical lung radiotherapy.
- Stable lab values: Hematological:
Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin≥9 g/dL Renal: Creatinine OR Measured or calculated creatinine clearance (CrCl)(glomerular filtration rate [GFR] can also be used in place of creatinine or CrCl) ≤1.5×the upper limit of normal (ULN) OR ≥60 mL/min for patient with creatinine levels>1.5× institutional ULN Hepatic: Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN for patients with total bilirubin levels >1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN,globulin≥20 g/L, albumin≥30 g/L.
- No relevant co-morbidities, including pulmonary fibrosis and connective tissue disorders
- Able to understand and give written informed consent and comply with study procedures.
Exclusion Criteria:
- Patient has had palliative radiotherapy to any tumour site prior to registration and/or requires palliative radiotherapy prior to randomisation.
- Patient has received any molecular targeted therapeutic drugs for NSCLC malignancy.
- The patients receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve progressive disease.
- Any unstable systemic disease, including active infection, uncontrolled high blood pressure, unstable angina, newly observed angina pectoris within the past 3 months, congestive heart failure (New York heart association (NYHA) class II or higher), myocardial infarction onset six months before included into the group, and severe arrhythmia, liver, kidney, or metabolic disease in need of drug therapy.
- Previously diagnosed with immunodeficiency disease.
- Human immunodeficiency virus (HIV) infection.
- Women in pregnancy or lactation.
- Patients with mental illness, considered as "can't fully understand the issues of this research".
- other Cancer history.
- Histologically confirmed small cell carcinoma or other non NSCLC compositions in the cancer tissue.
- Brain metastasis or liver metastasis or malignant pleural effusion or pericardial effusion or peritoneal effusion.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:Conventional Fractionated Radiotherapy
The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response).
Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
|
5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
|
实验性的:Stereotactic Body Radiation Therapy
The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response).
Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
|
30Gy/3-5F for the primary and the metastases.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
无进展生存
大体时间:2年
|
2年
|
次要结果测量
结果测量 |
大体时间 |
---|---|
总生存期
大体时间:2年
|
2年
|
治疗相关不良事件的发生率
大体时间:2年
|
2年
|
合作者和调查者
调查人员
- 研究主任:Xiaolong Fu、Shanghai Chest Hospital
出版物和有用的链接
一般刊物
- Salama JK, Schild SE. Radiation therapy for oligometastatic non-small cell lung cancer. Cancer Metastasis Rev. 2015 Jun;34(2):183-93. doi: 10.1007/s10555-015-9559-z.
- Hanna GG, Landau D. Stereotactic body radiotherapy for oligometastatic disease. Clin Oncol (R Coll Radiol). 2015 May;27(5):290-7. doi: 10.1016/j.clon.2015.02.003. Epub 2015 Mar 12.
- Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013 Jan;14(1):e28-37. doi: 10.1016/S1470-2045(12)70510-7.
- Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013 Nov;82(2):197-203. doi: 10.1016/j.lungcan.2013.07.026. Epub 2013 Aug 20.
- Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, Congedo MT, Gomez DR, Wright GM, Melloni G, Milano MT, Sole CV, De Pas TM, Carter DL, Warner AJ, Rodrigues GB. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2014 Sep;15(5):346-55. doi: 10.1016/j.cllc.2014.04.003. Epub 2014 May 15.
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
非小细胞肺癌的临床试验
-
Centre Oscar LambretUniversity Hospital, Lille终止
-
Spanish Lung Cancer Group完全的
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.完全的
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.完全的
-
Niguarda HospitalUniversity of Turin, Italy; Fondazione del Piemonte per l'Oncologia完全的
-
AstraZeneca完全的局部晚期或转移性 EGFR(+) NSCLC 患者中国
-
Mylan Pharmaceuticals Inc完全的NSCLC IV期火鸡, 台湾, 越南, 克罗地亚, 印度, 俄罗斯联邦, 西班牙, 匈牙利, 波斯尼亚和黑塞哥维那, 乌克兰, 波兰, 罗马尼亚, 白俄罗斯, 保加利亚, 乔治亚州, 意大利, 菲律宾
Conventional Fractionated Radiotherapy的临床试验
-
University Hospital, GhentJules Bordet Institute; AZ Sint-Lucas Gent; GZA Ziekenhuizen Campus Sint-Augustinus; AZ Sint-Lucas...完全的